Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul A Marks

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Seminars in Cancer Biology|November 11, 2006
Thioredoxin in cancer--role of histone deacetylase inhibitorsPaul A Marks
Cell Cycle (Georgetown, Tex.)|March 17, 2004
The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA)Paul A Marks
Oncology (Williston Park, N.Y.)|April 6, 2010
HDAC inhibitors: much to learn about effective therapyPaul A Marks
Expert Opinion on Investigational Drugs|August 7, 2010
The clinical development of histone deacetylase inhibitors as targeted anticancer drugsPaul A Marks
Biochimica Et Biophysica Acta|July 3, 2010
Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functionsPaul A Marks
Oncology (Williston Park, N.Y.)|May 10, 2011
Epigenetic targeted anti-cancer drugs: an unfolding storyPaul A Marks
The Journal of Clinical Investigation|April 3, 2008
The American Society for Clinical Investigation--the first 100 yearsPaul A Marks
Nature Biotechnology|January 11, 2007
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugPaul A Marks, Ronald Breslow
Journal of Cellular Biochemistry|August 10, 2005
Prospects: histone deacetylase inhibitorsMilos Dokmanovic, Paul A Marks
Cell Cycle (Georgetown, Tex.)|March 2, 2005
Histone deacetylase inhibitors in programmed cell death and cancer therapyPaul A Marks, Xuejun Jiang
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Seminars in Cancer Biology|November 11, 2006
Thioredoxin in cancer--role of histone deacetylase inhibitorsPaul A Marks
Cell Cycle (Georgetown, Tex.)|March 17, 2004
The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA)Paul A Marks
Oncology (Williston Park, N.Y.)|April 6, 2010
HDAC inhibitors: much to learn about effective therapyPaul A Marks
Expert Opinion on Investigational Drugs|August 7, 2010
The clinical development of histone deacetylase inhibitors as targeted anticancer drugsPaul A Marks
Biochimica Et Biophysica Acta|July 3, 2010
Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functionsPaul A Marks
Oncology (Williston Park, N.Y.)|May 10, 2011
Epigenetic targeted anti-cancer drugs: an unfolding storyPaul A Marks
The Journal of Clinical Investigation|April 3, 2008
The American Society for Clinical Investigation--the first 100 yearsPaul A Marks
Nature Biotechnology|January 11, 2007
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugPaul A Marks, Ronald Breslow
Journal of Cellular Biochemistry|August 10, 2005
Prospects: histone deacetylase inhibitorsMilos Dokmanovic, Paul A Marks
Cell Cycle (Georgetown, Tex.)|March 2, 2005
Histone deacetylase inhibitors in programmed cell death and cancer therapyPaul A Marks, Xuejun Jiang
Pageof 5